Indication and Limitation of Use

Vectibix® is indicated for the treatment of patients with wild-type KRAS (exon 2 in codons 12 or 13) metastatic colorectal cancer (mCRC) as determined by an FDA-approved test for this use: as first-line therapy in combination… read more

Vectibix® is indicated for the treatment of patients with wild-type KRAS (exon 2 in codons 12 or 13)… read more

Vectibix® is indicated for the treatment of patients with wild-type KRAS (exon 2 in codons 12 or 13) metastatic colorectal cancer (mCRC) as determined by an FDA-approved test… read more

Vectibix® is indicated for the treatment of patients with wild-type KRAS (exon 2 in codons 12 or 13) metastatic colorectal cancer (mCRC) as determined by an FDA-approved test for this use: as first-line therapy in combination with FOLFOX, as monotherapy following disease progression after prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy.

Vectibix® is not indicated for the treatment of patients with RAS-mutant mCRC or for whom RAS mutation status is unknown.

×
×

You are now leaving Vectibix.com

Please know that the sponsors of this site are not responsible for content on the site you are about to enter.

Cancel
Continue

Meet Connie*:

A patient with third-line mCRC

What clinical characteristics affect your third-line treatment decision?

  • Patient
  • Connie*
  • Gender
  • Female
  • Age
  • 68
  • Occupation
  • Salesperson

*A hypothetical case study of a patient eligible for third-line mCRC therapy.

  • Medical history
  • Osteoarthritis
  • Presentation
  • Initial presentation of mild abdominal discomfort and mild anemia
  • Colonoscopy revealed a non-obstructing mass in the left colon
  • CT scan revealed liver and lung metastases that were unresectable
  • Prior therapy
  • First-line treatment: FOLFOX + bevacizumab
    • Progressed on therapy after 9 months
  • Second-line treatment: FOLFIRI + bevacizumab
    • Progressed on therapy after 7 months with liver and lung metastases
  • Performance status
  • ECOG PS = 1
  • Laboratory results
  • ALT: 135 U/L; AST: 250 U/L
  • CBC
    • WBC: 4.0 x 103/μL
    • Neutrophil: 1.6 x 103/μL
    • Hb: 9.0 g/dL
    • PLT: 125 x 103/μL
  • Bilirubin: 1.8 mg/dL
  • Mutational status
  • KRAS wild type (not RAS mutant)
  • Imaging results
  • CT scan indicated diffuse metastatic involvement of lung and liver
  • Surgery consult on metastatic disease
  • Unresectable due to number of metastatic sites

ALT = alanine aminotransferase; AST = aspartate aminotransferase; CBC = complete blood count; CT = computed tomography; ECOG PS  = Eastern Cooperative Oncology Group Performance Status; Hb = hemoglobin; mCRC = metastatic colorectal cancer; PLT = platelet; WBC = white blood cell count.

Site Map
×